Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition-Reference-Cited by-同舟云学术

Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition

Published:2018-02 Issue: Volume:282 Page:13-21
ISSN:0009-2797
Container-title:Chemico-Biological Interactions
language:en
Short-container-title:Chemico-Biological Interactions

Author:

Patel Vishal,Joharapurkar Amit,Kshirsagar Samadhan,Sutariya Brijesh,Patel Maulik,Pandey Dheerendra,Patel Hiren,Ranvir Ramchandra,Kadam Shekhar,Patel Dipam,Bahekar Rajesh,Jain Mukul

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference42 articles.

1. Hyperlipidemia as a risk factor for cardiovascular disease;Nelson;Prim. Cardiol.,2013

2. Lipids, risk factors and ischaemic heart disease;Castelli;Atherosclerosis,1996

3. Low-density lipoprotein reduction and magnitude of cardiovascular risk reduction;Rahilly-Tierney;Prev. Cardiol.,2009

4. Effective strategies for long-term statin use;Fonarow;Am. J. Cardiol.,2003

5. Ineffectiveness of lipid-lowering therapy in primary care;Van;Br. J. Clin. Pharmacol.,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of glucagon and exenatide on oxidative stress levels and antioxidative enzyme expression in in vitro induced steatosis in HepG2 cell culture;Endokrynologia Polska;2024-08-09

2. Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs;Journal of Clinical Medicine;2024-08-09

3. Hepatic glucagon action: beyond glucose mobilization;Physiological Reviews;2024-07-01

4. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications;Therapeutic Advances in Endocrinology and Metabolism;2024-01

5. Liposomal Phytosterols as LDL-Cholesterol-Lowering Agents in Diet-Induced Hyperlipidemia;Molecular Pharmaceutics;2023-07-26